ClinicalTrials.gov
public full text
Public Domain
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021 and marketing authorization through the FDA De Novo process in September 2023.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients#901193
- Iron Accumulation in Erythrocytes in Patients#859587
- Congenital Hemolytic and Dyserythropoietic Anemias#890574
- RBL001/RBL002 Phase I Clinical Trial#136413
- Unmodified Versus Leuko-reduced Allogeneic Red Blood Cells Transfusion in Cancer Patients#1163389
Record · ID 876494
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive